Skip to main content

Table 3 Primary treatments of patients in BCA and HER2+ BCA study cohorts

From: Clinicopathological and prognostic correlations of HER3 expression and its degradation regulators, NEDD4–1 and NRDP1, in primary breast cancer

Primary treatment BCA cohort (n = 308) HER2-amplified BCA cohort (n = 177)
n % n %
Breast surgery
 Mastectomy (ablation) 161 52.4 101 57.1
 Conservative surgery (resection) 146 47.6 72 40.7
 No operation    3 0.6
 Unknown 1    
Post-operative radiotherapy 198 65.3 110 62.1
 No 105 34.7 67 37.9
 Unknown 5    
Adjuvant endocrine therapy 97 32.1 104 58.8
 No 205 67.9 73 41.2
 Unknown 6    
Adjuvant chemotherapy 40 13.4 133 75.1
 No 259 86.6 44 24.9
 Unknown 9    
Adjuvant trastuzumab    82 46.3
 No 308 100.0 95 53.7